U.S. Banks Stock News

Soleno Therapeutics stock overview Soleno Therapeutics (SLNO) has drawn fresh attention after a sharp 32.3% one day move, capping a month gain of 31.7%. That kind of short term swing naturally raises valuation and risk questions for investors. See our latest analysis for Soleno Therapeutics. The sharp 32.3% one day share price return and 71.7% 7 day share price return come after a 10.8% year to date share price gain, set against a 1 year total shareholder return of about 25% decline and a...

Dividend hike and full year results put International Bancshares in focus International Bancshares (IBOC) is back on investor radars after the board approved a $0.73 per share cash dividend, a 4.3% increase, alongside the release of full year 2025 financial results. See our latest analysis for International Bancshares. At a share price of $68.26, International Bancshares has seen a 1-day share price return of 0.72% and a 1-month share price return of 2.60%, while the 1-year total shareholder...

This article explores whether Liberty Energy's share price still reflects good value, or if the easier gains may already have occurred, by considering what the current price might be implying about the company. Liberty Energy closed at US$27.67, with a 4.1% decline over the last 7 days, a 3.2% gain over 30 days, a 46.6% return year to date, and a 169.7% return over the past year. Recent coverage has focused on Liberty Energy as part of broader discussions around US energy services companies...

Versigent PLC (NYSE:VGNT) has completed its spin-off from Aptiv’s Electrical Distribution Systems business, forming an independent publicly listed company. The separation was accompanied by a broad refresh of the board and executive team, including new CEO and CFO appointments and restructured board committees. Versigent converted from a limited company to a public limited company, adopted a new name and bylaws, and was added to several major equity benchmarks. Versigent now trades as...

MoonLake Immunotherapeutics recently reported long-term Week 40 Phase 3 VELA-1 and VELA-2 data for sonelokimab in moderate-to-severe hidradenitis suppurativa, showing strong efficacy on HiSCR75 and quality-of-life endpoints with a stable safety profile. An interesting feature of these results is the use of a higher HiSCR75 threshold as the primary endpoint, positioning sonelokimab against existing IL-17A and IL-17A/F therapies on a more stringent efficacy measure. We’ll now examine how...

Worthington Steel (WS) is back in focus after reporting third quarter results that showed higher sales but lower quarterly net income compared with a year earlier, along with higher nine-month earnings and a reaffirmed quarterly dividend. See our latest analysis for Worthington Steel. The latest results and dividend decision come after a mixed price pattern, with a 5.05% 7 day share price return, a 19.61% 30 day share price decline, and a 31.76% 1 year total shareholder return, suggesting...

In March 2026, Gilat Satellite Networks’ Gilat DataPath unit reported receiving about US$6,000,000 in new orders over six months to continue providing field and technical services that support U.S. Army global communications operations under the GTACS II contract vehicle. This extension deepens Gilat’s multi-year role in mission-critical U.S. defense communications, underscoring the company’s position as a trusted supplier of resilient connectivity for military operations. We’ll now examine...

Recent commentary highlights how PDF Solutions has been benefiting from AI-led digital transformation, as customers increasingly adopt its cloud-enabled software, unified data platforms, and real-time analytics to manage more complex semiconductor manufacturing. An important insight is that rising investments in 3D manufacturing, AI-driven collaboration, and geographic diversification are amplifying demand for PDF Solutions’ consulting, research, cybersecurity, and compliance-focused...

In late March 2026, Hudson Technologies announced a licensing agreement with Solstice Advanced Materials to reclaim and resell Solstice’s patented lower-GWP HFO refrigerant blends R-448A and R-449A across the United States and Canada under AIM Act-compliant applications in the supermarket segment. This agreement gives Solstice broader access to the refrigeration retrofit market while aligning its technology with tightening environmental regulations on higher-GWP refrigerants. Next, we’ll...

Why BofA’s New Coverage Matters For Payoneer Global (PAYO) BofA’s decision to initiate coverage of Payoneer Global (PAYO) with a favorable view puts fresh attention on the stock and highlights its role in cross border payments for small and medium sized businesses. See our latest analysis for Payoneer Global. Despite BofA’s positive coverage, momentum has been mixed. There has been a 7 day share price return of 3.14% and a 30 day share price return of 4.68%, set against a 1 year total...

In early April 2026, reports that the US government may impose tariffs of up to 100% on imports of branded and patented drugs, focusing on companies that have not agreed to lower prices, triggered a broad reassessment of regulatory and cost risks across the pharmaceutical industry. This policy debate matters for Collegium Pharmaceutical because it highlights how fast-changing US drug-pricing and trade actions can influence sentiment toward specialty pain and CNS drug makers, even when their...

Recently, analysts raised their full-year earnings projections for China Yuchai International by 40.5%, while the company’s year-to-date return has outpaced both the broader Auto-Tires-Trucks sector and its Automotive - Original Equipment peers. This combination of sharply upgraded earnings expectations and clear relative performance strength suggests analysts and investors are reassessing the company’s profit and competitive outlook. We’ll now explore how this upgrade in earnings...

Edwards Lifesciences (EW) put fresh clinical data for its EVOQUE tricuspid valve system in the spotlight at the ACC.26 conference, highlighting sustained patient benefits and lower mortality in the TRISCEND II trial. See our latest analysis for Edwards Lifesciences. At a share price of $81.19, Edwards Lifesciences has seen a 17.67% 1 year total shareholder return. The 90 day share price return of a 5.43% decline suggests recent momentum has cooled despite supportive EVOQUE trial headlines. If...

Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US based fill finish site. See our latest analysis for Scholar Rock Holding. The BLA resubmission appears to have kept attention on Scholar Rock, with a 7 day share price return of 13.3% and an 18.16% 90 day share price return. The 1 year total shareholder return of 87.44% points to strong momentum...

In recent months, Ormat Technologies has outlined plans to add 149 MW of new capacity by the end of 2027, including 101 MW from geothermal projects, while committing US$180 million to build additional energy storage assets in the United States through 2028. This combination of geothermal expansion and sizable storage investment highlights Ormat’s effort to deepen its role in supplying grid-stable renewable power as adoption of clean energy accelerates. Next, we’ll explore how Ormat’s planned...

Why CNA Financial (CNA) Is Back in Focus After Its Latest Quarter CNA Financial (CNA) has drawn fresh attention after quarterly results came in below market expectations, with weaker core earnings per share and profitability despite growth in premiums and investment income. At the same time, management raised the regular dividend by 4% and announced a special dividend. This move highlights confidence in ongoing cash generation, even as underwriting performance and higher expenses remain key...

In the fourth quarter of 2025, Medpace Holdings reported a 32% year-over-year revenue increase, while Mairs & Power Small Cap Fund cited the company as a key contributor in its investor letter due to stronger clinical trial trends linked to GLP-1 programs. This combination of healthier trial cancellation patterns and momentum in GLP-1 research highlights how Medpace is benefiting from current demand in metabolic-related clinical development. We’ll now explore how this improved GLP-1-driven...

On March 24, 2026, Ardent Health, Inc. announced that Ethan Chernin departed the company and would no longer serve as President, Hospital Services, with his separation treated as a “Qualifying Termination” under the firm’s Executive Severance Plan. This leadership change in a core operating role raises important questions about continuity in hospital operations and the company’s broader execution plans. We’ll now examine how the sudden exit of Ardent’s President of Hospital Services may...

Amylyx Pharmaceuticals (AMLX) shares are in focus after the company reported that the final participant has been randomized and dosed in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia. See our latest analysis for Amylyx Pharmaceuticals. The latest trial milestone arrives as momentum in Amylyx Pharmaceuticals' share price has been building, with a 7 day share price return of 23.98% and a 90 day share price return of 39.02%, set against a very large 1 year...

AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI...

Recent analysis of past performance shows that Service Corporation International has not increased the number of funeral services performed over the last two years, while also reporting weaker free cash flow margins and a declining return on invested capital compared with sector expectations. This combination of stagnant service volumes and deteriorating profitability metrics suggests the company may be contending with demand constraints and limited high-return reinvestment...

Helmerich & Payne has completed the sale of Tulsa’s Utica Square retail center, with after-tax proceeds exceeding its US$100 million divestiture target and earmarked largely to retire the company’s remaining term loan as part of a balance sheet-focused portfolio review. The move marks a significant shift away from non-core real estate and frees up financial capacity that can be redeployed toward Helmerich & Payne’s core drilling and technology operations following its capital-intensive KCA...

Acuity (AYI) is back in focus after its second quarter 2026 earnings, where adjusted earnings per share came in ahead of expectations while revenue lagged forecasts, highlighting contrasting trends across its Lighting and Intelligent Spaces businesses. See our latest analysis for Acuity. The share price reaction has been mixed, with a 1 day share price return of 1.06% after earnings but a 90 day share price return representing a 28.55% decline. However, the 3 year total shareholder return of...

Xeris Biopharma Holdings (XERS) drew fresh investor attention after reporting fourth quarter 2025 earnings per share of US$0.06 on revenue of US$85.8 million, both above prior projections and supported by a reiteration of positive analyst views. See our latest analysis for Xeris Biopharma Holdings. At a share price of US$6.05, Xeris Biopharma’s recent 8.04% 7 day share price return and 4.13% 30 day share price return contrast with a 17.69% decline year to date. At the same time, the 37.19% 1...